Iron status in patients with chronic heart failure

Jankowska, E.A. et al. (2013) Iron status in patients with chronic heart failure. European Heart Journal, 34(11), pp. 827-834. (doi: 10.1093/eurheartj/ehs377)

Full text not currently available from Enlighten.


<p>Aims: The changes in iron status occurring during the course of heart failure (HF) and the underlying pathomechanisms are largely unknown. Hepcidin, the major regulatory protein for iron metabolism, may play a causative role. We investigated iron status in a broad spectrum of patients with systolic HF in order to determine the changes in iron status in parallel with disease progression, and to associate iron status with long-term prognosis.</p> <p>Methods and results: Serum concentrations of ferritin, transferrin saturation (Tsat), soluble transferrin receptor (sTfR), and hepcidin were assessed as the biomarkers of iron status in 321 patients with chronic systolic HF [age: 61 ± 11 years, men: 84%, left ventricular ejection fraction: 31 ± 9%, New York Heart Association (NYHA) class: 72/144/87/18] at a tertiary cardiology centre and 66 age- and gender-matched healthy subjects. Compared with healthy subjects, asymptomatic HF patients had similar haematological status, but increased iron stores (evidenced by higher serum ferritin without distinct inflammation, P < 0.01) with markedly elevated serum hepcidin (P < 0.001). With increasing HF severity, patients in advanced NYHA classes had iron deficiency (ID) (reduced serum ferritin, low Tsat, high sTfR), iron-restricted erythropoiesis (reduced haemoglobin, high red cell distribution width), and inflammation (high serum high-sensitivity-C-reactive protein and interleukin 6), which was accompanied by decreased circulating hepcidin (all P < 0.001). In multivariable Cox models, low hepcidin was independently associated with increased 3-year mortality among HF patients (P < 0.001).</p> <p>Conclusions: Increased level of circulating hepcidin characterizes an early stage of HF, and is not accompanied by either anaemia or inflammation. The progression of HF is associated with the decline in circulating hepcidin and the development of ID. Low hepcidin independently relates to unfavourable outcome.</p>

Item Type:Articles
Glasgow Author(s) Enlighten ID:McMurray, Professor John
Authors: Jankowska, E.A., Malyszko, J., Ardehali, H., Koc-Zorawska, E., Banasiak, W., von Haehling, S., Macdougall, I.C., Weiss, G., McMurray, J.J.V., Anker, S.D., Gheorghiade, M., and Ponikowski, P.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:European Heart Journal
ISSN (Online):1522-9645
Published Online:23 November 2012

University Staff: Request a correction | Enlighten Editors: Update this record